# Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

> **NCT05752552** · PHASE1 · RECRUITING · sponsor: **DeuterOncology** · enrollment: 55 (estimated)

## Conditions studied

- Adult Solid Tumor
- Advanced Solid Tumor
- Refractory Tumor
- Non-small Cell Lung Cancer
- Non-small Cell Carcinoma
- Lung Cancer
- Hereditary Renal Papillary Cancer

## Interventions

- **DRUG:** DO-2

## Key facts

- **NCT ID:** NCT05752552
- **Lead sponsor:** DeuterOncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-20
- **Primary completion:** 2027-09
- **Final completion:** 2028-09
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05752552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05752552, "Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05752552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*